{"title":"中性粒细胞与淋巴细胞比率作为系统性红斑狼疮疾病活动性的替代标志物：使用SLE-DAS的相关性研究","authors":"Mandy Ming Yan Wong, Fung Lam, Chi Chiu Mok","doi":"10.1177/1759720X251347272","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The neutrophil-to-lymphocyte ratio (NLR) is a potential surrogate marker for disease activity in many rheumatic diseases.</p><p><strong>Objective: </strong>To study the correlation between NLR and disease activity of systemic lupus erythematosus (SLE) using the SLE disease activity score (SLE-DAS).</p><p><strong>Design: </strong>Retrospective, cross-sectional.</p><p><strong>Methods: </strong>Consecutive adult patients who fulfilled the American College of Rheumatology (ACR) or Systemic Lupus International Collaboration Clinic (SLICC) criteria for SLE were recruited between March 2023 and February 2024. SLE activity was assessed by physicians' global assessment (PGA), SLE-DAS, and SLE disease activity index-2000 (SLEDAI-2K). The calculated NLR was correlated with disease activity indices and serological parameters (anti-dsDNA, C3/4) by Spearman's rank correlation. Patients were stratified into SLE-DAS remission, mild, and moderate/severe disease activity, and a comparison of the NLR was performed among these subgroups by one-way ANOVA.</p><p><strong>Results: </strong>A total of 420 SLE patients were studied (93.1% women, age 31.6 ± 13.1 years, SLE duration 15.7 ± 8.1 years). Moderate/severe, mild disease activity and SLE-DAS remission were present in 70 (16.7%), 65 (15.5%), and 285 (67.9%) patients, respectively. SLE-DAS correlated significantly with SLEDAI-2K (rho 0.90; <i>p</i> < 0.001) and PGA (rho 0.60; <i>p</i> < 0.001). The mean NLR of all patients was 3.54 ± 4.0 and NLR correlated significantly with SLE-DAS (rho 0.17; <i>p</i> < 0.001). The NLR was significantly higher in patients with active disease in the SLE-DAS renal domain than those in remission (5.17 ± 7.11 vs 3.22 ± 3.19; <i>p</i> = 0.03). The NLR in patients with moderate/severe SLE-DAS activity (5.25 ± 6.89) was significantly higher than those with mild activity (3.12 ± 2.26; <i>p</i> < 0.01) or remission (3.22 ± 3.19; <i>p</i> < 0.01). ROC analysis showed that an NLR cut-off of 3.11 showed a sensitivity of 55.6% and specificity of 68.7% in detecting moderate/severe SLE-DAS activity (area under the curve 0.67 (0.6-0.7); <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>The NLR is a convenient marker that correlates significantly with disease activity in SLE.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"17 ","pages":"1759720X251347272"},"PeriodicalIF":3.4000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179458/pdf/","citationCount":"0","resultStr":"{\"title\":\"The neutrophil-to-lymphocyte ratio as a surrogate marker for disease activity in systemic lupus erythematosus: a correlation study using the SLE-DAS.\",\"authors\":\"Mandy Ming Yan Wong, Fung Lam, Chi Chiu Mok\",\"doi\":\"10.1177/1759720X251347272\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The neutrophil-to-lymphocyte ratio (NLR) is a potential surrogate marker for disease activity in many rheumatic diseases.</p><p><strong>Objective: </strong>To study the correlation between NLR and disease activity of systemic lupus erythematosus (SLE) using the SLE disease activity score (SLE-DAS).</p><p><strong>Design: </strong>Retrospective, cross-sectional.</p><p><strong>Methods: </strong>Consecutive adult patients who fulfilled the American College of Rheumatology (ACR) or Systemic Lupus International Collaboration Clinic (SLICC) criteria for SLE were recruited between March 2023 and February 2024. SLE activity was assessed by physicians' global assessment (PGA), SLE-DAS, and SLE disease activity index-2000 (SLEDAI-2K). The calculated NLR was correlated with disease activity indices and serological parameters (anti-dsDNA, C3/4) by Spearman's rank correlation. Patients were stratified into SLE-DAS remission, mild, and moderate/severe disease activity, and a comparison of the NLR was performed among these subgroups by one-way ANOVA.</p><p><strong>Results: </strong>A total of 420 SLE patients were studied (93.1% women, age 31.6 ± 13.1 years, SLE duration 15.7 ± 8.1 years). Moderate/severe, mild disease activity and SLE-DAS remission were present in 70 (16.7%), 65 (15.5%), and 285 (67.9%) patients, respectively. SLE-DAS correlated significantly with SLEDAI-2K (rho 0.90; <i>p</i> < 0.001) and PGA (rho 0.60; <i>p</i> < 0.001). The mean NLR of all patients was 3.54 ± 4.0 and NLR correlated significantly with SLE-DAS (rho 0.17; <i>p</i> < 0.001). The NLR was significantly higher in patients with active disease in the SLE-DAS renal domain than those in remission (5.17 ± 7.11 vs 3.22 ± 3.19; <i>p</i> = 0.03). The NLR in patients with moderate/severe SLE-DAS activity (5.25 ± 6.89) was significantly higher than those with mild activity (3.12 ± 2.26; <i>p</i> < 0.01) or remission (3.22 ± 3.19; <i>p</i> < 0.01). ROC analysis showed that an NLR cut-off of 3.11 showed a sensitivity of 55.6% and specificity of 68.7% in detecting moderate/severe SLE-DAS activity (area under the curve 0.67 (0.6-0.7); <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>The NLR is a convenient marker that correlates significantly with disease activity in SLE.</p>\",\"PeriodicalId\":23056,\"journal\":{\"name\":\"Therapeutic Advances in Musculoskeletal Disease\",\"volume\":\"17 \",\"pages\":\"1759720X251347272\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179458/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Musculoskeletal Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/1759720X251347272\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Musculoskeletal Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1759720X251347272","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：中性粒细胞与淋巴细胞比率（NLR）是许多风湿性疾病疾病活动性的潜在替代标志物。目的：应用系统性红斑狼疮（SLE）疾病活动性评分（SLE- das）研究NLR与SLE疾病活动性的相关性。设计：回顾性，横断面。方法：在2023年3月至2024年2月期间，连续招募符合美国风湿病学会（ACR）或系统性狼疮国际合作诊所（SLICC） SLE标准的成年患者。通过医师整体评估（PGA）、SLE- das和SLE疾病活动指数-2000 （SLEDAI-2K）评估SLE活动性。计算的NLR与疾病活动性指数和血清学参数（抗dsdna， C3/4）采用Spearman秩相关。将患者分为SLE-DAS缓解、轻度和中度/重度疾病活动度，并通过单因素方差分析比较这些亚组之间的NLR。结果：共纳入420例SLE患者（93.1%为女性，年龄31.6±13.1岁，病程15.7±8.1年）。分别有70例（16.7%）、65例（15.5%）和285例（67.9%）患者出现中度/重度、轻度疾病活动和SLE-DAS缓解。sledai - das与SLEDAI-2K显著相关(rho 0.90；p p p p = 0.03)。中度/重度SLE-DAS活动期患者NLR（5.25±6.89）显著高于轻度活动期患者(3.12±2.26；结论：NLR是一种方便的与SLE疾病活动度相关的标志物。
The neutrophil-to-lymphocyte ratio as a surrogate marker for disease activity in systemic lupus erythematosus: a correlation study using the SLE-DAS.
Background: The neutrophil-to-lymphocyte ratio (NLR) is a potential surrogate marker for disease activity in many rheumatic diseases.
Objective: To study the correlation between NLR and disease activity of systemic lupus erythematosus (SLE) using the SLE disease activity score (SLE-DAS).
Design: Retrospective, cross-sectional.
Methods: Consecutive adult patients who fulfilled the American College of Rheumatology (ACR) or Systemic Lupus International Collaboration Clinic (SLICC) criteria for SLE were recruited between March 2023 and February 2024. SLE activity was assessed by physicians' global assessment (PGA), SLE-DAS, and SLE disease activity index-2000 (SLEDAI-2K). The calculated NLR was correlated with disease activity indices and serological parameters (anti-dsDNA, C3/4) by Spearman's rank correlation. Patients were stratified into SLE-DAS remission, mild, and moderate/severe disease activity, and a comparison of the NLR was performed among these subgroups by one-way ANOVA.
Results: A total of 420 SLE patients were studied (93.1% women, age 31.6 ± 13.1 years, SLE duration 15.7 ± 8.1 years). Moderate/severe, mild disease activity and SLE-DAS remission were present in 70 (16.7%), 65 (15.5%), and 285 (67.9%) patients, respectively. SLE-DAS correlated significantly with SLEDAI-2K (rho 0.90; p < 0.001) and PGA (rho 0.60; p < 0.001). The mean NLR of all patients was 3.54 ± 4.0 and NLR correlated significantly with SLE-DAS (rho 0.17; p < 0.001). The NLR was significantly higher in patients with active disease in the SLE-DAS renal domain than those in remission (5.17 ± 7.11 vs 3.22 ± 3.19; p = 0.03). The NLR in patients with moderate/severe SLE-DAS activity (5.25 ± 6.89) was significantly higher than those with mild activity (3.12 ± 2.26; p < 0.01) or remission (3.22 ± 3.19; p < 0.01). ROC analysis showed that an NLR cut-off of 3.11 showed a sensitivity of 55.6% and specificity of 68.7% in detecting moderate/severe SLE-DAS activity (area under the curve 0.67 (0.6-0.7); p < 0.001).
Conclusion: The NLR is a convenient marker that correlates significantly with disease activity in SLE.
期刊介绍：
Therapeutic Advances in Musculoskeletal Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of musculoskeletal disease.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
